Customer support

xie@china-sinoway.com
English
banner
Products
Home

Polypeptides

Decapeptide-12 137665-91-9

Decapeptide-12 137665-91-9

98% up by HPLC
  • Product Details

Product Information


Product name

Decapeptide-12

CAS No.

137665-91-9

Sequence

H-Tyr-Arg-Ser-Arg-Lys-Tyr-Ser-Ser-Trp-Tyr-OH

Molecular Formula

C33H65N5O5

Molecular Weight

1395.55

Quality Standard

98% up by HPLC

Appearance

White lyophilized powder


COA of Decapeptide-12


TEST

SPECIFICATION

RESULTS

Appearance

White Powder

Complies

Odor

Characteristic

Complies

Tasted

Characteristic

Complies

Assay

99%

Complies

Sieve Analysis

100% pass 80 mesh

Complies

Loss on Drying

5% Max.

1.02%

Sulphated Ash

5% Max.

1.3%

Extract Solvent

Ethanol & Water

Complies

Heavy Metal

5ppm Max

Complies

As

2ppm Max

Complies

Residual Solvents

0.05% Max.

Negative

Microbiology

Total Plate Count

1000/g Max

Complies

Yeast & Mold

100/g Max

Complies

E.Coli

Negative

Complies

Salmonella

Negative

Complies

Conclusion

Conforms with the standards



Usage

Function of Decapeptide-12


Decapeptide-12 is a cosmetic raw material that inhibits the formation of melanin, diminishes pigmentation, reduces pigmentation, and even and brightens the skin tone. It was developed by researchers from the Department of Dermatology at Stanford University. It is currently the only one that has been proven to effectively inhibit the skin A novel peptide with tyrosinase activity.


Decapeptide-12 can inhibit the synthesis of tyrosinase, thereby effectively (40%) reducing the production of melanin. It can minimize chloasma, freckles, age spots, sunburn, uneven skin tone and light damage caused by over-pigmentation. And decapeptide-12 does not have the toxicity and side effects of other whitening ingredients such as hydroquinone, such as allergies, irritation and redness.


 

Application of Decapeptide-12

Decapeptide-12 is always used in skin linghtening creams,serums,gel,lotion.

Send A Message

If you are interested in our products and want to know more details,please leave a message here,we will reply you as soon as we can.
Related Products

LIRAGLUTIDE
LIRAGLUTIDE 204656-20-2
Product Information Product name Liraglutide Sequence H-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu- Glu-Gly-Gln-Ala-Ala-Lys[N6-[N-(1-oxohexadecyl)-L-γ-glutamyl]- -Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly-OH CAS No. 204656-20-2 Molecular Formula C172H265N43O51 Molecular Weight 3751.20 Storage  2~8℃ Appearance White to off-white crystalline powder COA of Liraglutide Test Specification Results Appearance: White to off-white crystalline powder or lumps White powder Identity: 3751.2±1.0 3751.1 Purity (By HPLC) : Not Less than 98.0%; 99.51% Residual solvents: ≤0.25%total; ≤0.1%individual; ≤0.01%CH2CN Complies Related Peptide Total Impurity ≤ 2.0% Largest Single Impurity ≤ 1.0% TI =0.41% LSI =0.25% Peptide Content: Not Less than 85.0% 87.7% Water (K.F.): Not more than 5% 4.2% Acetate acid: Not more than 10% 8.1% Bacterial Endotoxins Not more than 50IU/mg Complies Usage Function and Usage of Liraglutide 204656-20-2 1、 Type 2 diabetes Liraglutide improves control of blood glucose.It reduces meal-related hyperglycemia (for 24 hours after administration) by increasing insulin secretion (only) when required by increasing glucose levels, delaying gastric emptying, and suppressing prandial glucagon secretion. In common to various degrees with other GLP-1 receptor agonists, liraglutide has advantages over more traditional therapies for type 2 diabetes: ·         Liraglutide acts in a glucose-dependent manner, meaning it will stimulate insulin secretion only when blood glucose levels are higher than normal, preventing "overshoot". Consequently, it shows negligible risk of hypoglycemia. ·         Liraglutide has the potential for inhibiting apoptosis and stimulating regeneration of beta cells (seen in animal studies). ·         Liraglutide decreases appetite and inhibits body weight gain, as shown in a head-to-head study versus glimepiride. ·         Liraglutide lowers blood triglyceride levels. 2、Obesity Liraglutide has been approved as an injectable adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients. The specified criteria are an initial body mass index (BMI) of 30 kg/m2 or greater (obese), or 27 kg/m2 or greater (overweight), in the presence of at least one weight-related comorbid condition (e.g.hypertension, type 2 diabetes mellitus, or dyslipidemia). In late 2014, data were reported from the SCALE™ Obesity and Prediabetes trial, which is a randomised, double-blind, placebo-controlled, multinational trial in non-diabetic people with obesity and non-diabetic people who are overweight with comorbidities. In this phase 3a trial, there were 3,731 participants randomised to treatment with liraglutide 3 mg or placebo, both in combination with diet and exercise. Those who completed the 56-week trial achieved an average weight loss of 9.2%, to be compared with a 3.5% reduction in the placebo group.
matrixyl 3000
MATRIXYL 3000
Cosmetic Grade
nonapeptide-1
Nonapeptide-1
99% up by HPLC, Cosmetic Grade
Linaclotide
Linaclotide 851199-59-2
98% up, Medical Grade
Send A Message
Send A Message
If you are interested in our products and want to know more details,please leave a message here,we will reply you as soon as we can.

Home

Products

about

Contact